TYK Medicines-B(02410): ESMO 2025 Congress to announce positive clinical data on multiple CDK inhibitors.

TYK Medicines-B (02410) announced that the company's board of directors is pleased to announce the early clinical research results of three drugs in the area of cell cycle protein-dependent kinase inhibitors (CDKi) that are key focus areas for the company. These three drugs are TYK-00540 (CDK2/4i), TY-2699a (CDK7i), and TY-302 (CDK4/6i), and the results will be presented in poster format at the European Society for Medical Oncology (ESMO) annual meeting. The ESMO 2025 conference will be held in Berlin, Germany from October 17-21, 2025. As one of the most influential academic conferences in the field of oncology worldwide, the ESMO annual meeting attracts numerous top experts and scholars in the field, providing a platform for discussing clinical challenges and sharing cutting-edge advancements.